Computer-aided detection during colonoscopy has become one of diagnostic AI's genuine early success stories, and this comparison exists partly to preserve the distinction that success rests on: detection, characterisation and autonomous treatment decisions are three different functions, and every product in this category currently occupies the first, real-time visual assistance helping the endoscopist see lesions they might otherwise miss, rather than the latter two.
The comparison, dimension by dimension
Polyp detection: the core function across all three, real-time visual flagging of suspicious regions during the live procedure. Lesion characterisation: a more advanced and less universally mature capability, distinguishing likely lesion type rather than simply flagging its presence. Visual alerts and integration with endoscopy hardware: how each system presents its flags to the endoscopist and how tightly it integrates with existing procedure equipment, a practical adoption consideration as much as a technical one. Real-time latency: detection assistance that lags the live image meaningfully is of limited practical use during a moving procedure. Adenoma-detection rate and adenoma-miss rate: the two headline outcome measures this category is evaluated against, detection rate capturing how many adenomas are found overall, miss rate capturing how many are overlooked on a first pass that a second look reveals. False alerts: the unglamorous but clinically important cost side, since excessive false flagging can fatigue endoscopists or prolong procedures without improving detection meaningfully. Withdrawal time: whether AI assistance changes how long endoscopists spend examining the bowel during withdrawal, itself an established quality metric independent of AI. Regulatory indications and evidence from tandem and parallel trials: the study designs this category relies on most heavily, and worth understanding precisely, since tandem studies specifically measure miss rate by re-examining the same segment.
The headline result, and what a tandem study actually measures
GI Genius became the first FDA-authorised AI-assisted polyp-detection system via the De Novo pathway, a genuinely novel authorisation route reflecting that nothing quite like it existed as a comparator device before. A tandem study, where the same colon segment is examined twice, once with and once without AI assistance, to directly measure what a first pass misses, reported an adenoma-miss rate of approximately 15.5% with AI assistance versus 32.4% without it. This is a meaningful and directly interpretable result precisely because of the tandem design: it measures missed lesions directly rather than inferring miss rate indirectly, and roughly halving the miss rate is a substantial improvement in a category where even experienced endoscopists have well-documented miss rates for adenomas, particularly smaller and flatter lesions that are easier to overlook. Fujifilm's CAD EYE subsequently received US clearance building on a broadly similar real-time detection proposition, and Olympus has introduced its OLYSENSE endoscopy-AI platform into the same category, both entering a space GI Genius's authorisation and evidence base helped establish.
Why a lower miss rate is not yet proven cancer prevention
The critical interpretation this article insists on stating plainly: a lower adenoma-miss rate is a meaningful and clinically sensible intermediate outcome, more adenomas found and removed during colonoscopy plausibly reduces the pool of lesions that could progress to cancer, and it does not, by itself, directly quantify the reduction in future colorectal-cancer incidence or mortality that would be the category's ultimate clinical goal. Establishing that link definitively requires the kind of long-horizon outcome follow-up this whole cluster keeps identifying as the hardest and rarest evidence tier to obtain, tracking detected-and-removed adenomas through to actual downstream cancer rates over years, evidence that is biologically plausible given what is already known about the adenoma-carcinoma sequence but that remains a distinct and harder claim than the miss-rate result alone establishes.
What the category has not yet automated
Worth restating precisely because it is easy to lose in enthusiasm about strong detection results: none of these three systems makes autonomous treatment decisions, and lesion characterisation, distinguishing which flagged lesions need removal versus surveillance versus reassurance, remains a less mature capability than detection itself across the category. The endoscopist's judgement about what to do with a flagged lesion, and the pathologist's subsequent characterisation of anything removed, remain fully in human hands; these systems extend the eye, not the decision.
Frequently asked questions
Does a halved adenoma-miss rate mean colorectal cancer rates will halve too?
Not directly: the relationship between removing more adenomas and reducing future cancer incidence is biologically plausible and supported by the broader adenoma-carcinoma evidence base, but the magnitude of that downstream effect requires its own long-term outcome studies rather than being read straight off the miss-rate result.
Do these systems tell the endoscopist what a flagged lesion actually is?
Detection and characterisation are different capabilities, and while some characterisation functionality is emerging across the category, the mature and most evidenced function remains real-time detection, flagging that something is present for the endoscopist's own assessment.
Could AI assistance increase procedure time or false alerts enough to offset its benefit?
It is a genuine trade-off worth monitoring locally, since false-alert burden and any change in withdrawal time affect both procedure efficiency and endoscopist experience, and services adopting these systems should track these alongside detection metrics rather than assuming detection benefit alone settles the cost-benefit question.